Alberto Corsini Selected Research

Glucose (Dextrose)

1/2022	Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity?
1/2021	Proprotein Convertase Subtilisin/Kexin Type 9: A View beyond the Canonical Cholesterol-Lowering Impact.
1/2020	Clinical Pharmacology of Statins: an Update.
1/2018	Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract.
7/2011	Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alberto Corsini Research Topics

Disease

25	Cardiovascular Diseases (Cardiovascular Disease) 03/2022 - 05/2003
18	Atherosclerosis 05/2022 - 11/2004
13	Inflammation (Inflammations) 02/2022 - 11/2005
11	Muscular Diseases (Myopathy) 01/2018 - 05/2002
7	Type 2 Diabetes Mellitus (MODY) 11/2021 - 02/2009
7	Neoplasms (Cancer) 08/2021 - 11/2005
6	Acute Coronary Syndrome 05/2022 - 01/2007
6	Hypertension (High Blood Pressure) 01/2022 - 05/2003
6	Coronary Disease (Coronary Heart Disease) 06/2020 - 12/2002
6	Dyslipidemias (Dyslipidemia) 03/2020 - 01/2005
5	Drug-Related Side Effects and Adverse Reactions 01/2018 - 08/2011
4	Myalgia 05/2022 - 05/2015
4	Diabetes Mellitus 03/2022 - 06/2014
4	Hypercholesterolemia 10/2021 - 01/2008
4	Obesity 07/2021 - 01/2019
4	Atherosclerotic Plaque (Atheroma) 04/2021 - 07/2009
4	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 11/2004
3	Stroke (Strokes) 05/2022 - 01/2018
3	Insulin Resistance 01/2022 - 06/2006
3	Heart Failure 01/2022 - 03/2013
3	COVID-19 12/2021 - 09/2020
3	Hypertriglyceridemia 10/2021 - 05/2017
3	Liver Diseases (Liver Disease) 07/2021 - 05/2013
3	Injection Site Reaction 07/2020 - 01/2017
3	Rhabdomyolysis 03/2003 - 05/2002
2	Atrial Fibrillation 05/2022 - 01/2021
2	Venous Thromboembolism 05/2022 - 10/2014
2	Hyperlipidemias (Hyperlipidemia) 02/2022 - 03/2003
2	Non-alcoholic Fatty Liver Disease 01/2022 - 07/2021
2	Alzheimer Disease (Alzheimer's Disease) 06/2019 - 01/2017
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2018 - 06/2006
1	Hemorrhage 05/2022
1	Ischemic Stroke 05/2022
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 05/2022
1	Myocardial Infarction 01/2022
1	Fibrosis (Cirrhosis) 01/2022
1	Tachycardia (Tachyarrhythmias) 01/2022

Drug/Important Bio-Agent (IBA)

32	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 05/2022 - 05/2002
17	CholesterolIBA 02/2022 - 10/2005
16	LipidsIBA 03/2022 - 03/2003
9	oxidized low density lipoproteinIBA 02/2022 - 01/2007
9	Triglycerides (Triacylglycerol)IBA 01/2022 - 11/2005
7	LDL CholesterolIBA 10/2021 - 11/2005
7	Proteins (Proteins, Gene)FDA Link 08/2021 - 02/2012
7	Pharmaceutical PreparationsIBA 07/2021 - 12/2002
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2006
6	Lipoprotein(a)IBA 01/2022 - 07/2020
6	Lipoproteins (Lipoprotein)IBA 01/2022 - 05/2017
5	Transaminases (Aminotransferases)IBA 03/2022 - 06/2004
5	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 07/2011
5	EnzymesIBA 01/2021 - 08/2011
4	Atorvastatin (Lipitor)FDA Link 05/2022 - 05/2002
4	C-Reactive ProteinIBA 07/2021 - 11/2018
4	Proprotein Convertase 9IBA 04/2021 - 02/2016
4	PPAR alphaIBA 09/2019 - 11/2005
4	Fibric Acids (Fibrates)IBA 05/2017 - 03/2003
4	ApolipoproteinsIBA 01/2017 - 11/2007
3	Monoclonal AntibodiesIBA 10/2021 - 06/2020
3	Oxidoreductases (Dehydrogenase)IBA 06/2020 - 12/2002
3	Immunosuppressive Agents (Immunosuppressants)IBA 03/2020 - 03/2003
3	HDL LipoproteinsIBA 01/2019 - 11/2012
3	HDL CholesterolIBA 01/2019 - 11/2005
3	CalponinsIBA 11/2017 - 07/2015
3	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 07/2015 - 05/2002
3	Fluvastatin FDA Link 01/2008 - 01/2004
2	LDL Lipoproteins (beta Lipoproteins)IBA 02/2022 - 01/2019
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2022 - 01/2020
2	RNA (Ribonucleic Acid)IBA 01/2022 - 07/2020
2	eicosapentaenoic acid ethyl esterIBA 10/2021 - 01/2020
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 10/2021 - 05/2017
2	LDL Receptors (LDL Receptor)IBA 01/2021 - 07/2015
2	evolocumabIBA 11/2020 - 06/2020
2	Coenzyme A (CoA)IBA 06/2020 - 03/2003
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2019 - 06/2013
2	CytokinesIBA 01/2018 - 11/2012
2	pitavastatin (itavastatin)FDA Link 01/2015 - 08/2011
2	Pravastatin (Pravachol)FDA LinkGeneric 01/2015 - 01/2008
2	Bile Acids and Salts (Bile Acids)IBA 05/2013 - 02/2009
2	Indicators and Reagents (Reagents)IBA 05/2010 - 10/2006
2	Simvastatin (Zocor)FDA LinkGeneric 01/2008 - 05/2002
2	Lovastatin (Mevacor)FDA LinkGeneric 01/2008 - 05/2002
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 03/2003 - 05/2002
2	cerivastatin (Kazak)FDA Link 12/2002 - 05/2002
1	apixabanIBA 05/2022
1	AnticoagulantsIBA 05/2022
1	edoxabanIBA 05/2022
1	Warfarin (Coumadin)FDA LinkGeneric 05/2022
1	Dabigatran FDA Link 05/2022
1	RivaroxabanIBA 05/2022
1	Ezetimibe (Zetia)FDA Link 02/2022
1	PolyphenolsIBA 02/2022
1	Angiotensin Receptor AntagonistsIBA 01/2022
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2022
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2022

Therapy/Procedure

17	Therapeutics 11/2021 - 12/2002
4	Polypharmacy 05/2022 - 11/2012
4	Secondary Prevention 06/2020 - 01/2004
2	Kidney Transplantation 03/2020 - 01/2005
2	Drug Therapy (Chemotherapy) 06/2013 - 12/2002
1	Stents 01/2022